Real-Time Monitoring for Viral Hepatitis

HBV and HCV RT-PCR kits enable baseline viral load quantification, antiviral therapy monitoring, and sustained virologic response confirmation with rapid turnaround and WHO-calibrated standards.

Partner With Us
OVERVIEW

Hepatitis B & C Demand Rapid Detection

Accurate viral load quantification and pan-genotypic detection enable timely diagnosis, treatment monitoring, and sustained virologic response confirmation in HBV & HCV infections.

287M

Chronic Hepatitis Cases

Source: WHO Global Hepatitis Report 2026

Link

1.3M

Hepatitis-Related Deaths

Source: WHO Global Hepatitis Report 2026

Link

240M

Chronic HBV Cases

Source: WHO Global Hepatitis Report 2026

Link

THE MEDINNO APPROACH

A scalable workflow designed to reduce the cost of population-wide testing

SCREENING WORKFLOW

Geographic Mapping

Antibody-positive samples are referred for confirmatory Real-Time PCR testing to establish active HBV or HCV infection status.

SCREENING WORKFLOW

Community Mobilization

Quantify initial HBV DNA or HCV RNA levels to assess treatment eligibility and establish prognostic disease severity.

SCREENING WORKFLOW

Sample Collection

Real-Time PCR detection compatible with HBV genotypes A through H and HCV genotypes one through six for accurate viral load quantification.

SCREENING WORKFLOW

Rapid Molecular Testing

Establish baseline viral load assessment and genotype profiling before initiating antiviral or direct-acting antiviral therapy protocols.

SCREENING WORKFLOW

Treatment Linkage & Reporting

Track viral suppression and response at defined monitoring intervals during active antiviral or DAA therapy course.

Technology

Screening Technology Beyond Labs

HBV and HCV RT-PCR solutions enable rapid detection and quantification with streamlined workflows and standardized accuracy.

Nucleic Acid Extraction

Automated extraction of HBV DNA and HCV RNA from serum with integrated inhibitor controls ensuring high-fidelity template preparation for downstream amplification.

Targeted Real-Time PCR

Real-Time PCR detection compatible with HBV genotypes A–H and HCV genotypes 1–6, with WHO-standardized quantification: HBV (25 IU/mL to 10⁷ IU/mL) and HCV (40 IU/mL to 10⁷ IU/mL).

Field-Ready Infrastructure

Validated performance on standard 4-channel and 5-channel Real-Time PCR platforms, enabling deployment across clinical laboratories, hospitals, and diagnostic centers without equipment replacement.

Impact On Systems

Greater Rural Reach

Open-system Real-Time PCR compatibility enables HBV and HCV testing deployment across resource-limited hospitals and diagnostic centers without proprietary equipment.

Impact On Systems

Faster Case Notification

InnoAmp HBV and HCV reagent pricing reduces cost per patient report by thirty to fifty percent versus closed systems.

Impact On Systems

Reduced Loss to Follow-Up

HBV and HCV amplification completes in sixty to ninety minutes post-extraction, enabling same-day diagnostic reporting from clinical laboratories.

FOR LOW-RESOURCE SETTINGS

Designed for gaps in standard diagnostic systems.

Clinical laboratories in remote regions face electricity shortages, inadequate infrastructure, and limited technical expertise. InnoAmp HBV & HCV assays are engineered for reliability under these constraints, with optimized reagents, portable equipment compatibility, minimal temperature requirements, and offline data logging for seamless deployment in underserved diagnostic settings.
Collaboration

Mass screening is most effective as a public-health effort.

Government Health Departments Public Health & Multilateral Bodies NGOs & Global Health Foundations CSR & Corporate Partners
icon

Government Health Departments

National healthcare systems require reliable molecular diagnostics to detect and monitor HBV & HCV infections. InnoAmp RT-PCR assays provide rapid results and standardized accuracy, supporting centralized testing strategies and treatment initiation across underserved populations.

icon

Public Health & Multilateral Bodies

International health organizations depend on standardized diagnostic protocols for hepatitis elimination initiatives. InnoAmp's pan-genotypic detection and open-system compatibility facilitate deployment across diverse laboratory settings while maintaining cross-border result harmonization.

icon

NGOs & Global Health Foundations

Nonprofit screening programs need cost-effective molecular diagnostics for field deployment. InnoAmp's 30–50% cost reduction versus closed systems makes large-scale HBV & HCV testing feasible in underserved communities.

icon

CSR & Corporate Partners

Corporate-funded hepatitis initiatives require scalable diagnostic solutions without proprietary equipment mandates. InnoAmp enables workplace and community screening programs with rapid reporting and minimal infrastructure requirements.

Transform Your Hepatitis Diagnostic Capacity

Partner with us to integrate InnoAmp RT-PCR diagnostics into your laboratory or screening program. Access rapid, accurate, WHO-calibrated viral testing with cost-effective scalability across resource-limited and clinical settings.

Get In Touch